BMS-986460

BMS-986460 is an investigational small molecule drug developed by Bristol Myers Squibb for the treatment of metastatic castration-resistant prostate cancer. It is classified as a ligand-directed degrader, designed to specifically and simultaneously bind to tumor-associated antigens on prostate tumor cells and E3 ubiquitin ligase, leading to targeted protein degradation within cancer cells. The drug is currently in Phase 1 clinical trials evaluating its safety, tolerability, and preliminary efficacy in men with advanced or metastatic prostate cancer that has progressed despite androgen deprivation therapy and prior secondary hormonal therapies[1][2][3][5][7].